Combination therapy with anti-DR5 antibody and tamoxifen for triple negative breast cancer

References

• Ichikawa K, Liu W, Zhao L, Wang Z, Liu D, Ohtsuka T, Zhang H, Mountz JD, Koopman WJ, Kimberly RP, et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 2001; 7:954 - 60; http://dx.doi.org/10.1038/91000; PMID: 11479629
   PubMed Web of Science ®Google Scholar
• Rahman M, Davis SR, Pumphrey JG, Bao J, Nau MM, Meltzer PS, Lipkowitz S. TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype. Breast Cancer Res Treat 2009; 113:217 - 30; http://dx.doi.org/10.1007/s10549-008-9924-5; PMID: 18266105
   PubMed Web of Science ®Google Scholar
• Oliver PG, Lobuglio AF, Zhou T, Forero A, Kim H, Zinn KR, et al. Effect of anti-DR5 and chemotherapy on basal-like breast cancer. Breast Cancer Res Treat 2012; 133:417 - 26; PMID: 21901385
   PubMed Web of Science ®Google Scholar
• Zhai G, Kim H, Sarver D, Samuel S, Whitworth L, Umphrey H, et al. Early therapy assessment of combined anti-DR5 antibody and carboplatin in triple-negative breast cancer xenografts in mice using diffusion-weighted imaging and H MR spectroscopy. Journal of magnetic resonance imaging. J Magn Reson Imaging 2014; 39:1588 - 94
   PubMed Web of Science ®Google Scholar
• Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005; 11:5678 - 85; http://dx.doi.org/10.1158/1078-0432.CCR-04-2421; PMID: 16115903
   PubMed Web of Science ®Google Scholar
• Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007; 13:2329 - 34; http://dx.doi.org/10.1158/1078-0432.CCR-06-1109; PMID: 17438091
   PubMed Web of Science ®Google Scholar
• Forero-Torres A, Shah J, Wood T, Posey J, Carlisle R, Copigneaux C, Luo FR, Wojtowicz-Praga S, Percent I, Saleh M. Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5). Cancer Biother Radiopharm 2010; 25:13 - 9; http://dx.doi.org/10.1089/cbr.2009.0673; PMID: 20187792
   PubMed Web of Science ®Google Scholar
• Miller WR, Anderson TJ, Dixon JM, Saunders PT. Oestrogen receptor beta and neoadjuvant therapy with tamoxifen: prediction of response and effects of treatment. Br J Cancer 2006; 94:1333 - 8; http://dx.doi.org/10.1038/sj.bjc.6603082; PMID: 16622466
   PubMed Web of Science ®Google Scholar
• Rose DP, Chlebowski RT, Connolly JM, Jones LA, Wynder EL. Effects of tamoxifen adjuvant therapy and a low-fat diet on serum binding proteins and estradiol bioavailability in postmenopausal breast cancer patients. Cancer Res 1992; 52:5386 - 90; PMID: 1394142
   PubMed Web of Science ®Google Scholar
• Green S, Walter P, Kumar V, Krust A, Bornert JM, Argos P, Chambon P. Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature 1986; 320:134 - 9; http://dx.doi.org/10.1038/320134a0; PMID: 3754034
   PubMed Web of Science ®Google Scholar
• Greene GL, Gilna P, Waterfield M, Baker A, Hort Y, Shine J. Sequence and expression of human estrogen receptor complementary DNA. Science 1986; 231:1150 - 4; http://dx.doi.org/10.1126/science.3753802; PMID: 3753802
   PubMed Web of Science ®Google Scholar
• Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A 1996; 93:5925 - 30; http://dx.doi.org/10.1073/pnas.93.12.5925; PMID: 8650195
   PubMed Web of Science ®Google Scholar
• Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998; 339:1609 - 18; http://dx.doi.org/10.1056/NEJM199811263392207; PMID: 9828250
   PubMed Web of Science ®Google Scholar
• Skliris GP, Leygue E, Curtis-Snell L, Watson PH, Murphy LC. Expression of oestrogen receptor-beta in oestrogen receptor-alpha negative human breast tumours. Br J Cancer 2006; 95:616 - 26; http://dx.doi.org/10.1038/sj.bjc.6603295; PMID: 16880783
   PubMed Web of Science ®Google Scholar
• Honma N, Horii R, Iwase T, Saji S, Younes M, Takubo K, Matsuura M, Ito Y, Akiyama F, Sakamoto G. Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. J Clin Oncol 2008; 26:3727 - 34; http://dx.doi.org/10.1200/JCO.2007.14.2968; PMID: 18669459
   PubMed Web of Science ®Google Scholar
• Yan M, Rayoo M, Takano EA, Fox SB, kConFab Investigators. Nuclear and cytoplasmic expressions of ERβ1 and ERβ2 are predictive of response to therapy and alters prognosis in familial breast cancers. Breast Cancer Res Treat 2011; 126:395 - 405; http://dx.doi.org/10.1007/s10549-010-0941-9; PMID: 20490651
   PubMed Web of Science ®Google Scholar
• Razandi M, Pedram A, Jordan VC, Fuqua S, Levin ER. Tamoxifen regulates cell fate through mitochondrial estrogen receptor beta in breast cancer. Oncogene 2013; 32:3274 - 85; http://dx.doi.org/10.1038/onc.2012.335; PMID: 22907432
   PubMed Web of Science ®Google Scholar
• Ozben T. Oxidative stress and apoptosis: impact on cancer therapy. J Pharm Sci 2007; 96:2181 - 96; http://dx.doi.org/10.1002/jps.20874; PMID: 17593552
   PubMed Web of Science ®Google Scholar
• Gruvberger-Saal SK, Bendahl PO, Saal LH, Laakso M, Hegardt C, Edén P, Peterson C, Malmström P, Isola J, Borg A, et al. Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma. Clin Cancer Res 2007; 13:1987 - 94; http://dx.doi.org/10.1158/1078-0432.CCR-06-1823; PMID: 17404078
   PubMed Web of Science ®Google Scholar
• Gorin MB, Day R, Costantino JP, Fisher B, Redmond CK, Wickerham L, Gomolin JE, Margolese RG, Mathen MK, Bowman DM, et al. Long-term tamoxifen citrate use and potential ocular toxicity. Am J Ophthalmol 1998; 125:493 - 501; http://dx.doi.org/10.1016/S0002-9394(99)80190-1; PMID: 9559735
   PubMed Web of Science ®Google Scholar
• Kim H, Chaudhuri TR, Buchsbaum DJ, Wang D, Zinn KR. High-resolution single-photon emission computed tomography and X-ray computed tomography imaging of Tc-99m-labeled anti-DR5 antibody in breast tumor xenografts. Mol Cancer Ther 2007; 6:866 - 75; http://dx.doi.org/10.1158/1535-7163.MCT-06-0230; PMID: 17363481
   PubMed Web of Science ®Google Scholar
• Gajate C, Mollinedo F. The antitumor ether lipid ET-18-OCH(3) induces apoptosis through translocation and capping of Fas/CD95 into membrane rafts in human leukemic cells. Blood 2001; 98:3860 - 3; http://dx.doi.org/10.1182/blood.V98.13.3860; PMID: 11739199
   PubMed Web of Science ®Google Scholar
• Cremesti A, Paris F, Grassmé H, Holler N, Tschopp J, Fuks Z, Gulbins E, Kolesnick R. Ceramide enables fas to cap and kill. J Biol Chem 2001; 276:23954 - 61; http://dx.doi.org/10.1074/jbc.M101866200; PMID: 11287428
   PubMed Web of Science ®Google Scholar
• Delmas D, Rébé C, Lacour S, Filomenko R, Athias A, Gambert P, Cherkaoui-Malki M, Jannin B, Dubrez-Daloz L, Latruffe N, et al. Resveratrol-induced apoptosis is associated with Fas redistribution in the rafts and the formation of a death-inducing signaling complex in colon cancer cells. J Biol Chem 2003; 278:41482 - 90; http://dx.doi.org/10.1074/jbc.M304896200; PMID: 12902349
   PubMed Web of Science ®Google Scholar
• Fanzo JC, Lynch MP, Phee H, Hyer M, Cremesti A, Grassme H, Norris JS, Coggeshall KM, Rueda BR, Pernis AB, et al. CD95 rapidly clusters in cells of diverse origins. Cancer Biol Ther 2003; 2:392 - 5; http://dx.doi.org/10.4161/cbt.2.4.442; PMID: 14508111
   PubMed Web of Science ®Google Scholar
• Dumitru CA, Gulbins E. TRAIL activates acid sphingomyelinase via a redox mechanism and releases ceramide to trigger apoptosis. Oncogene 2006; 25:5612 - 25; http://dx.doi.org/10.1038/sj.onc.1209568; PMID: 16636669
   PubMed Web of Science ®Google Scholar
• Wagner KW, Punnoose EA, Januario T, Lawrence DA, Pitti RM, Lancaster K, Lee D, von Goetz M, Yee SF, Totpal K, et al. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med 2007; 13:1070 - 7; http://dx.doi.org/10.1038/nm1627; PMID: 17767167
   PubMed Web of Science ®Google Scholar
• Kim H, Zhai G, Samuel SL, Rigell CJ, Umphrey HR, Rana S, Stockard CR, Fineberg NS, Zinn KR. Dual combination therapy targeting DR5 and EMMPRIN in pancreatic adenocarcinoma. Mol Cancer Ther 2012; 11:405 - 15; http://dx.doi.org/10.1158/1535-7163.MCT-11-0581; PMID: 22203731
   PubMed Web of Science ®Google Scholar
• Kim H, Morgan DE, Buchsbaum DJ, Zeng H, Grizzle WE, Warram JM, Stockard CR, McNally LR, Long JW, Sellers JC, et al. Early therapy evaluation of combined anti-death receptor 5 antibody and gemcitabine in orthotopic pancreatic tumor xenografts by diffusion-weighted magnetic resonance imaging. Cancer Res 2008; 68:8369 - 76; http://dx.doi.org/10.1158/0008-5472.CAN-08-1771; PMID: 18922909
   PubMed Web of Science ®Google Scholar
• Kim H, Morgan DE, Zeng H, Grizzle WE, Warram JM, Stockard CR, Wang D, Zinn KR. Breast tumor xenografts: diffusion-weighted MR imaging to assess early therapy with novel apoptosis-inducing anti-DR5 antibody. Radiology 2008; 248:844 - 51; http://dx.doi.org/10.1148/radiol.2483071740; PMID: 18710978
   PubMed Web of Science ®Google Scholar
• Kisanga ER, Gjerde J, Guerrieri-Gonzaga A, Pigatto F, Pesci-Feltri A, Robertson C, Serrano D, Pelosi G, Decensi A, Lien EA. Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial. Clin Cancer Res 2004; 10:2336 - 43; http://dx.doi.org/10.1158/1078-0432.CCR-03-0538; PMID: 15073109
   PubMed Web of Science ®Google Scholar
• Jordan VC. Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance. Breast Cancer Res Treat 1982; 2:123 - 38; http://dx.doi.org/10.1007/BF01806449; PMID: 6184101
   PubMedGoogle Scholar
• Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, Hayes DF, Desta Z, Flockhart DA. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003; 95:1758 - 64; http://dx.doi.org/10.1093/jnci/djg108; PMID: 14652237
   PubMed Web of Science ®Google Scholar
• Buchsbaum DJ, Zhou T, Grizzle WE, Oliver PG, Hammond CJ, Zhang S, Carpenter M, LoBuglio AF. Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. Clin Cancer Res 2003; 9:3731 - 41; PMID: 14506165
   PubMed Web of Science ®Google Scholar
• Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193:265 - 75; PMID: 14907713
   PubMed Web of Science ®Google Scholar
• Kim H, Chaudhuri TR, Buchsbaum DJ, Wang D, Zinn KR. Single-photon emission computed tomography imaging with a humanized, apoptosis-inducing antibody targeting human death receptor 5 in pancreas and breast tumor xenografts. Cancer Biol Ther 2007; 6:1396 - 402; http://dx.doi.org/10.4161/cbt.6.9.4540
   Web of Science ®Google Scholar
• Neter J, Kutner MH, Nachtsheim JC, Wasserman W. Applied linear statistical models. Columbus: The McGraw-Hill Companies, Inc., 1996.
   Google Scholar